Vertex Pharmaceuticals Incorporated
VRTX
$394.17
-$3.19-0.80%
| Weiss Ratings | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Good | |||
| Risk Grade | B | |||
| Reward Grade | B | |||
| Rating Factors | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Good | |||
| Beta / Standard Deviation | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.44 | |||
| Price History | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.80% | |||
| 30-Day Total Return | -7.39% | |||
| 60-Day Total Return | -7.44% | |||
| 90-Day Total Return | 14.30% | |||
| Year to Date Total Return | -2.47% | |||
| 1-Year Total Return | 20.22% | |||
| 2-Year Total Return | 37.75% | |||
| 3-Year Total Return | 85.59% | |||
| 5-Year Total Return | 119.61% | |||
| 52-Week High % Change | -11.56% | |||
| 52-Week Low % Change | 25.32% | |||
| Price | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $448.40 | |||
| 52-Week Low Price | $316.43 | |||
| 52-Week Low Price (Date) | Apr 26, 2023 | |||
| 52-Week High Price (Date) | Jan 30, 2024 | |||
| Valuation | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 102.49B | |||
| Enterprise Value | 89.58B | |||
| Price/Earnings (TTM) | 28.55 | |||
| Earnings Per Share (TTM) | 13.89 | |||
| Earnings Per Share Growth | 8.33% | |||
| Price/Earnings To Growth | 3.43 | |||
| Price/Sales (TTM) | 10.48 | |||
| Price/Book (Q) | 5.81 | |||
| Enterprise Value/Revenue (TTM) | 9.08 | |||
| Price | $400.76 | |||
| Enterprise Value/EBITDA (TTM) | 20.01 | |||
| Enterprise Value/EBIT | 20.80 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 260.90M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 341 6100 | |||
| Address | 50 Northern Avenue Boston, MA 02210 | |||
| Website | www.vrtx.com | |||
| Country | United States | |||
| Year Founded | 1989 | |||
| Profitability | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 43.64% | |||
| Profit Margin | 36.67% | |||
| Management Effectiveness | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 13.17% | |||
| Return on Equity | 22.99% | |||
| Income Statement | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.87B | |||
| Total Revenue (TTM) | 9.87B | |||
| Revenue Per Share | $37.83 | |||
| Gross Profit (TTM) | 5.44B | |||
| EBITDA (TTM) | 4.48B | |||
| EBIT (TTM) | 4.31B | |||
| Net Income (TTM) | 3.62B | |||
| Net Income Avl. to Common (TTM) | 3.62B | |||
| Total Revenue Growth (Q YOY) | 9.34% | |||
| Earnings Growth (Q YOY) | 18.31% | |||
| EPS Diluted (TTM) | 13.89 | |||
| EPS Diluted Growth (Q YOY) | 18.08% | |||
| Balance Sheet | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.22B | |||
| Cash Per Share (Q) | $43.00 | |||
| Total Current Assets (Q) | 14.14B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 17.58B | |||
| Current Ratio (Q) | 3.987 | |||
| Book Value Per Share (Q) | $68.22 | |||
| Total Assets (Q) | 22.73B | |||
| Total Current Liabilities (Q) | 3.55B | |||
| Total Debt (Q) | 808.40M | |||
| Total Liabilities (Q) | 5.15B | |||
| Total Common Equity (Q) | 17.58B | |||
| Cash Flow | VRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -3.14B | |||
| Cash from Financing (TTM) | -562.20M | |||
| Net Change in Cash (TTM) | -139.70M | |||
| Levered Free Cash Flow (TTM) | 3.51B | |||
| Cash from Operations (TTM) | 3.54B | |||
